HC Wainwright set a $8.00 price target on ChromaDex (NASDAQ:CDXC) in a report released on Monday. The brokerage currently has a buy rating on the stock.

Other equities research analysts have also recently issued reports about the company. ValuEngine raised ChromaDex from a sell rating to a hold rating in a research report on Thursday, February 8th. Zacks Investment Research cut ChromaDex from a hold rating to a sell rating in a research report on Monday, February 12th. Finally, BidaskClub cut ChromaDex from a hold rating to a sell rating in a research report on Friday, January 26th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the stock. The stock has a consensus rating of Hold and an average target price of $7.50.

ChromaDex opened at $3.72 on Monday, Marketbeat Ratings reports. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.71 and a current ratio of 5.22. ChromaDex has a one year low of $3.60 and a one year high of $3.73.

ChromaDex (NASDAQ:CDXC) last released its quarterly earnings data on Thursday, May 10th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.09). ChromaDex had a negative net margin of 70.19% and a negative return on equity of 56.28%. The business had revenue of $6.57 million for the quarter, compared to analysts’ expectations of $6.50 million. research analysts expect that ChromaDex will post -0.34 earnings per share for the current fiscal year.

In other news, COO Robert N. Fried bought 10,000 shares of the stock in a transaction on Tuesday, May 15th. The shares were bought at an average price of $3.63 per share, with a total value of $36,300.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Frank L. Jaksch, Jr. sold 24,578 shares of the stock in a transaction dated Tuesday, March 27th. The shares were sold at an average price of $4.60, for a total value of $113,058.80. The disclosure for this sale can be found here. In the last three months, insiders acquired 22,800 shares of company stock worth $82,282. 11.59% of the stock is owned by corporate insiders.

A number of hedge funds have recently bought and sold shares of the business. Millennium Management LLC lifted its holdings in ChromaDex by 61.1% in the fourth quarter. Millennium Management LLC now owns 542,994 shares of the company’s stock valued at $3,193,000 after acquiring an additional 205,852 shares during the period. UBS Group AG lifted its holdings in ChromaDex by 94.1% in the first quarter. UBS Group AG now owns 121,412 shares of the company’s stock valued at $510,000 after acquiring an additional 58,848 shares during the period. BlackRock Inc. lifted its holdings in ChromaDex by 9.8% in the fourth quarter. BlackRock Inc. now owns 111,207 shares of the company’s stock valued at $654,000 after acquiring an additional 9,917 shares during the period. Oppenheimer & Co. Inc. lifted its holdings in ChromaDex by 117.6% in the first quarter. Oppenheimer & Co. Inc. now owns 92,500 shares of the company’s stock valued at $389,000 after acquiring an additional 50,000 shares during the period. Finally, Tibra Equities Europe Ltd bought a new position in ChromaDex in the first quarter valued at about $320,000. 9.82% of the stock is currently owned by institutional investors.

ChromaDex Company Profile

ChromaDex Corporation operates as a nutraceutical company. The company offers research and quality control products and services to dietary supplements, food, beverages, cosmetic, and pharmaceutical industries; Nicotinamide riboside (NIAGEN), a novel form of vitamin B3 for enhancing nicotinamide adenine dinucleotide(NAD) level used for healthy aging; Pterostilbene (pTeroPure), a polyphenol and antioxidant used in health related fields; and Immulina, a spirulina extract and compound, which is used for improving human immune function, as well as developing Pterostilbene and caffeine co-crystal ingredients, and anthocyanins ingredients.

Receive News & Ratings for ChromaDex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChromaDex and related companies with MarketBeat.com's FREE daily email newsletter.